Xvivo Perfusion Toekomstige groei

Future criteriumcontroles 5/6

Xvivo Perfusion zal naar verwachting groeien in winst en omzet met respectievelijk 26.3% en 29.4% per jaar. De winst per aandeel zal naar verwachting groeien met 25.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.4% zijn.

Belangrijke informatie

26.3%

Groei van de winst

25.9%

Groei van de winst per aandeel

Medical Equipment winstgroei	36.9%
Inkomstengroei	29.4%
Toekomstig rendement op eigen vermogen	11.4%
Dekking van analisten	Good
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 27

Recent updates

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 04

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 27

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Oct 25

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30

Winst- en omzetgroeiprognoses

OM:XVIVO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,525	302	150	401	5
12/31/2025	1,138	175	-4	244	6
12/31/2024	825	123	6	178	5
9/30/2024	751	204	-118	67	N/A
6/30/2024	699	121	-103	69	N/A
3/31/2024	643	100	-93	60	N/A
12/31/2023	598	92	-98	46	N/A
9/30/2023	573	24	-72	50	N/A
6/30/2023	524	27	-86	42	N/A
3/31/2023	463	28	-108	25	N/A
12/31/2022	415	18	-103	28	N/A
9/30/2022	370	30	-127	6	N/A
6/30/2022	328	23	-138	-20	N/A
3/31/2022	293	7	-138	-32	N/A
12/31/2021	258	8	-106	-12	N/A
9/30/2021	233	-24	-116	-33	N/A
6/30/2021	221	-37	-104	-27	N/A
3/31/2021	192	-44	-79	-11	N/A
12/31/2020	180	-44	-77	-12	N/A
9/30/2020	182	-26	-68	3	N/A
6/30/2020	194	-6	-54	20	N/A
3/31/2020	220	12	-49	39	N/A
12/31/2019	221	5	-54	30	N/A
9/30/2019	217	12	-37	34	N/A
6/30/2019	203	7	-42	23	N/A
3/31/2019	193	9	-41	15	N/A
12/31/2018	188	13	-31	24	N/A
9/30/2018	171	13	-21	34	N/A
6/30/2018	162	13	N/A	38	N/A
3/31/2018	153	10	N/A	33	N/A
12/31/2017	148	6	N/A	22	N/A
9/30/2017	145	0	N/A	8	N/A
6/30/2017	145	0	N/A	6	N/A
3/31/2017	142	0	N/A	5	N/A
12/31/2016	138	2	N/A	13	N/A
9/30/2016	132	5	N/A	22	N/A
6/30/2016	127	7	N/A	19	N/A
3/31/2016	122	6	N/A	20	N/A
12/31/2015	120	5	N/A	9	N/A
9/30/2015	113	4	N/A	-1	N/A
6/30/2015	109	4	N/A	1	N/A
3/31/2015	98	3	N/A	-7	N/A
12/31/2014	85	5	N/A	-5	N/A
9/30/2014	79	6	N/A	9	N/A
6/30/2014	74	7	N/A	3	N/A
3/31/2014	71	7	N/A	6	N/A
12/31/2013	69	8	N/A	13	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei XVIVO ( 26.3% per jaar) ligt boven de spaarquote ( 1.2% ).

Winst versus markt: De winst van XVIVO ( 26.3% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15% per jaar).

Hoge groeiwinsten: De winst van XVIVO zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van XVIVO ( 29.4% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0% per jaar).

Hoge groei-inkomsten: De omzet van XVIVO ( 29.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen XVIVO zal naar verwachting over 3 jaar laag zijn ( 11.4 %).

Xvivo Perfusion Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 11%, revenue upgraded

Consensus EPS estimates fall by 13%, revenue upgraded

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Consensus EPS estimates increase by 19%

Price target increased by 16% to kr509

Price target increased by 8.1% to kr450

Recent updates

Consensus EPS estimates fall by 11%, revenue upgraded

Independent Director recently bought kr346k worth of stock

Xvivo Perfusion AB (publ) Appoints Lena Hagman as Deputy Chief Executive Officer

Consensus EPS estimates fall by 13%, revenue upgraded

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

New major risk - Earnings quality

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Consensus EPS estimates increase by 19%

Price target increased by 16% to kr509

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.1% to kr450

Consensus EPS estimates increase by 10%

Now 20% undervalued

Independent Director recently bought kr222k worth of stock

Consensus EPS estimates increase by 27%

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Consensus EPS estimates increase by 16%

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Consensus EPS estimates increase by 17%, revenue downgraded

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Chairman of the Board recently bought kr281k worth of stock

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Price target increased by 7.9% to kr407

Consensus EPS estimates fall by 13%

Price target increased by 8.0% to kr407

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Consensus EPS estimates fall by 24%

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 24% undervalued

New minor risk - Shareholder dilution

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Consensus EPS estimates increase by 42%

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Consensus EPS estimates fall by 33%

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

Consensus EPS estimates fall by 12%

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Consensus revenue estimates increase by 10%

Independent Director recently bought kr107k worth of stock

Consensus EPS estimates fall by 30%

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Now 22% undervalued

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Now 21% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Consensus EPS estimates fall by 12%

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Consensus EPS estimates increase by 14%